Pipecuronium Uses, Dosage, Side Effects & Mechanism | DrugsAtlas
Authoritative Clinical Reference
Navigation
DRUG NAME: Pipecuronium
Therapeutic Class: Neuromuscular Blocking Agent
Subclass: Non-depolarising Aminosteroid Muscle Relaxant
Speciality: Anaesthesiology
Schedule (India): Schedule H
Route(s): Intravenous (IV)
Formulations Available in India:
- Injection: 4 mg/2 mL vial (lyophilised powder for reconstitution)
INDICATIONS + DOSING — FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
▶ Adjunct to General Anaesthesia for Skeletal Muscle Relaxation and Endotracheal Intubation
Adult Dosing — Intraoperative Use
| Parameter | Recommendation |
|
Starting dose (intubation)
|
0.06–0.08 mg/kg IV bolus |
|
Onset of action
|
2–4 minutes |
|
Duration of block
|
60–90 minutes |
|
Titration
|
Not applicable for bolus; adjust maintenance based on TOF monitoring |
|
Usual maintenance dose
|
0.01–0.015 mg/kg IV every 30–60 minutes as required |
|
Maximum single dose
|
0.1 mg/kg |
Clinical Notes:
- Neuromuscular monitoring (Train-of-Four stimulation) mandatory
- Titrate to maintain 1–2 twitches on TOF during surgery
- Ensure full reversal before extubation
Adult Dosing — ICU Paralysis (Ventilation Facilitation)
| Parameter | Recommendation |
|
Starting dose
|
0.04–0.05 mg/kg IV bolus |
|
Titration
|
Adjust infusion rate based on TOF monitoring every 4–6 hours |
|
Usual maintenance dose
|
Continuous infusion: 1–2 µg/kg/min |
|
Maximum dose
|
Titrate to lowest effective dose; no defined maximum for infusion |
Clinical Notes:
- Specialist critical care supervision mandatory
- Daily drug holidays recommended to assess neurological status
- Use shortest duration possible to minimise critical illness myopathy risk
- Ensure adequate sedation and analgesia before paralysis
Secondary Indications — Adults (Off-label, if any)
Not applicable — No established off-label indications in Indian practice.
PAEDIATRIC DOSING (Specialist Only)
Primary Indications (Approved / Standard in India)
▶ Adjunct to General Anaesthesia for Intubation and Maintenance of Muscle Paralysis
Age-Based Dosing Table
| Age Group | Intubation Dose (IV) | Maintenance Dose | Clinical Notes |
|
Neonates
|
0.04–0.06 mg/kg | 0.01 mg/kg every 30–60 min | Prolonged action likely; close TOF monitoring essential |
|
Infants (1 month–1 year)
|
0.04–0.08 mg/kg | 0.01 mg/kg every 30–60 min | Higher sensitivity; start at lower end |
|
Children (1–12 years)
|
0.05–0.09 mg/kg | 0.01–0.015 mg/kg every 30–60 min | Titrate to TOF response |
|
Adolescents (>12 years)
|
Same as adult dosing | Same as adult dosing | — |
Safety Monitoring:
- Continuous neuromuscular monitoring (TOF) mandatory
- Ensure full ventilatory and thermal support
- Monitor for prolonged paralysis particularly in neonates and infants
- PICU setting required for any continuous infusion use
Minimum Age Statement:
Use in neonates only under specialist paediatric anaesthesia supervision with neuromuscular monitoring facilities.
Use in neonates only under specialist paediatric anaesthesia supervision with neuromuscular monitoring facilities.
Secondary Indications — Paediatrics (Off-label, if any)
Not applicable — No established off-label paediatric uses in Indian practice.
RENAL ADJUSTMENT
| Renal Function | Recommendation |
|
Mild impairment (eGFR 60–89)
|
Use standard dose; monitor duration of block |
|
Moderate impairment (eGFR 30–59)
|
Reduce initial dose by 20–30%; extend dosing intervals |
|
Severe impairment (eGFR <30)
|
Reduce initial dose by 40–50%; avoid repeated dosing without TOF monitoring |
|
Dialysis
|
Not significantly removed; avoid continuous infusion if possible |
Note: Pipecuronium undergoes significant renal elimination; prolonged half-life expected in renal impairment. Neuromuscular monitoring essential in all cases.
HEPATIC ADJUSTMENT
| Hepatic Function | Recommendation |
|
Mild impairment (Child-Pugh A)
|
Start at lower end of dosing range |
|
Moderate impairment (Child-Pugh B)
|
Use with caution; reduce maintenance doses by 20–30%; monitor closely |
|
Severe impairment (Child-Pugh C)
|
Use with extreme caution; specialist anaesthesia input mandatory; expect prolonged duration |
CONTRAINDICATIONS
- Known hypersensitivity to pipecuronium or other aminosteroid NMBAs (vecuronium, rocuronium, pancuronium)
- Myasthenia gravis (unless ventilated and under specialist care)
- Eaton-Lambert myasthenic syndrome
- Unventilated patients with respiratory compromise
- Known family history of malignant hyperthermia (relative; avoid triggering agents concurrently)
CAUTIONS
- Electrolyte disturbances (hypokalaemia, hypocalcaemia, hypermagnesaemia) — may potentiate block
- Respiratory acidosis or alkalosis — alters blockade duration
- Concurrent high-dose corticosteroid therapy — increased risk of prolonged weakness
- Pre-existing neuromuscular disorders (muscular dystrophies, peripheral neuropathies)
- Elderly, frail, or cachectic patients — increased sensitivity
- Burns patients — may develop resistance; higher doses may be needed
- Prolonged ICU use — risk of critical illness polyneuropathy/myopathy
- Hypothermia — prolongs duration of action
- Obesity — dose on ideal body weight, not actual weight
PREGNANCY
| Parameter | Recommendation |
|
Risk Category
|
Category C — Use only if clearly needed |
|
Safety Data
|
Limited data in Indian obstetric practice |
|
Preferred Alternatives
|
Atracurium or cisatracurium preferred for Caesarean section (organ-independent elimination) |
|
When May Be Used
|
If no alternative available; under specialist anaesthesia supervision |
|
Monitoring
|
Maternal: uterine tone; Fetal/Neonatal: respiratory effort at delivery |
LACTATION
| Parameter | Recommendation |
|
Compatibility
|
Likely compatible for single operative use |
|
Milk Levels
|
Minimal expected; quaternary ammonium compound with poor oral bioavailability |
|
Preferred Alternatives
|
None specifically preferred; all NMBAs have similar profile |
|
Breastfeeding Interruption
|
Not required after standard anaesthesia doses |
|
Infant Monitoring
|
Monitor for feeding difficulty if maternal anaesthesia prolonged |
ELDERLY
| Parameter | Recommendation |
|
Starting Dose
|
Reduce by 20–30% compared to younger adults |
|
Titration
|
Slower titration; expect prolonged duration of action |
|
Special Risks
|
Reduced renal clearance, increased sensitivity to NMBAs, prolonged recovery |
|
Monitoring
|
Neuromuscular monitoring essential; ensure full reversal before extubation |
MAJOR DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Management |
|
Volatile anaesthetics (isoflurane, sevoflurane, desflurane)
|
Potentiate neuromuscular block; reduce pipecuronium requirement by 25–40% | Reduce maintenance doses; monitor TOF closely |
|
Aminoglycosides (gentamicin, amikacin, streptomycin)
|
Synergistic neuromuscular blockade | Avoid combination if possible; if used, reduce NMBA dose and monitor |
|
Magnesium sulphate
|
Marked potentiation of block | Caution in eclampsia/pre-eclampsia management; reduce dose significantly |
|
Polymyxins (colistin, polymyxin B)
|
Additive neuromuscular blockade | Avoid concurrent use if possible |
|
Clindamycin/Lincomycin
|
Potentiate neuromuscular blockade | Use with caution; monitor closely |
MODERATE DRUG INTERACTIONS
| Interacting Drug/Class | Effect | Management |
|
Loop diuretics (furosemide)
|
Electrolyte shifts may prolong blockade | Monitor electrolytes; replace potassium as needed |
|
Calcium channel blockers (verapamil, diltiazem)
|
May enhance neuromuscular block | Monitor duration of block; adjust doses if needed |
|
High-dose corticosteroids
|
Prolonged weakness with ICU use | Use lowest effective NMBA dose; daily drug holidays |
|
Lithium
|
May enhance neuromuscular block | Monitor closely; reduce NMBA dose if needed |
|
Phenytoin/Carbamazepine
|
Chronic use may cause resistance to NMBAs | May require higher doses; acute use may potentiate |
|
Quinidine/Procainamide
|
Potentiate neuromuscular block | Monitor duration of paralysis |
COMMON ADVERSE EFFECTS
- Prolonged neuromuscular blockade (dose-related)
- Transient hypotension (minimal; less than tubocurarine)
- Bradycardia (especially with concurrent opioids or volatile anaesthetics)
- Injection site irritation
SERIOUS ADVERSE EFFECTS
- Respiratory paralysis requiring prolonged mechanical ventilation
- Anaphylaxis/anaphylactoid reactions (rare; cross-sensitivity with other NMBAs possible)
- Residual postoperative neuromuscular weakness
- Critical illness polyneuropathy/myopathy (with prolonged ICU infusion)
- Cardiovascular collapse (rare; in susceptible patients)
MONITORING REQUIREMENTS
| Phase | Parameters |
|
Baseline
|
Serum electrolytes (K⁺, Ca²⁺, Mg²⁺), renal function, hepatic function, body weight |
|
Intraoperative
|
Train-of-Four (TOF) or peripheral nerve stimulator continuously; target 1–2 twitches |
|
ICU Use
|
TOF monitoring every 4–6 hours; daily neurological examination during drug holidays |
|
Pre-extubation
|
Ensure TOF ratio ≥0.9; sustained head lift ≥5 seconds; adequate tidal volumes |
|
Post-operative
|
Monitor for residual weakness, respiratory adequacy |
BRANDS AVAILABLE IN INDIA
- Arduan® (Gedeon Richter / marketed by Dr. Reddy’s)
- Limited generic availability
PRICE RANGE (INR)
| Formulation | Price Range | Notes |
| 4 mg/2 mL vial | ₹150–₹250 | Private sector pricing |
- Not included in NLEM; not under NPPA price control
- Primarily available through tertiary hospital OT/ICU procurement
CLINICAL PEARLS
- Cardiovascular stability: Minimal histamine release compared to benzylisoquinolinium NMBAs (atracurium, mivacurium) — preferred in haemodynamically unstable patients
- Long duration: 60–90 minute block duration makes it unsuitable for short procedures; consider rocuronium or vecuronium for cases <45 minutes
- Renal dependence: Significant renal elimination — use cautiously in renal impairment; atracurium or cisatracurium preferred for renal failure patients
- Reversal: Sugammadex efficacy for pipecuronium is NOT established (unlike rocuronium/vecuronium); use neostigmine (0.05 mg/kg) with glycopyrrolate (0.01 mg/kg) or atropine for reversal
- ICU caution: Prolonged use (>48–72 hours) increases risk of critical illness myopathy; implement daily interruption protocols
- Obesity dosing: Calculate dose based on ideal body weight, not actual body weight, to avoid overdosing
TAGS
pipecuronium; non-depolarising muscle relaxant; aminosteroid NMBA; neuromuscular blockade; general anaesthesia; intubation; ICU paralysis; renal-caution; elderly-caution; long-acting NMBA
VERSION
RxIndia v0.2 — 03 Feb 2026
REFERENCES
- CDSCO approved prescribing information
- Indian Pharmacopoeia
- Product insert — Arduan® (Dr. Reddy’s, India)
- Goodman & Gilman’s: The Pharmacological Basis of Therapeutics
- AIIMS Anaesthesia protocols (tertiary hospital practice)
- Miller’s Anesthesia (reference for pharmacokinetic data)
- Indian specialist anaesthesia and critical care practice guidelines
⚖️
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.